


Management options – Reported treatment effectiveness varies with age of initiation, treatment duration, compliance as well as demographic/environmental factors.

**Prevention**




**Slowing progression**


**Spectacle option**




**Highly Aspherical Lenslets (HAL)**  
2 years  
 $\Delta$ SphE 0.80 D (55%)  
 $\Delta$ AL 0.35 mm (51%)




**Defocus Incorporated Multiple Segments (DIMS)**  
2 years  
 $\Delta$ SphE 0.44 D (52%)  
 $\Delta$ AL 0.34 mm (62%)




**Diffusion Optics Technology (DOT)**  
1 year  
 $\Delta$ SphE 0.40 D (74%)  
 $\Delta$ AL 0.15 mm (50%)



**Executive Prismatic Bifocals (+1.50 D add)**  
3 years  
 $\Delta$ SphE 1.05 D (51%)  
 $\Delta$ AL 0.28 mm (34%)



**Progressive Addition Lens (PALS)**  
2 years  
 $\Delta$ SphE 0.14 D (24%)  
 $\Delta$ AL 0.04 mm (28%)




**Peripheral Hyperopia Reduction Lens**  
2 years  
 $\Delta$ SphE 0.04 D (3%)  
 $\Delta$ AL 0.04 mm (5%)

**Contact lens option**



**Dual Focus**  
3 years  
 $\Delta$ SphE 0.73 D (59%)  
 $\Delta$ AL 0.32 mm (52%)  
US FDA approved



**Extended Depth of Focus**  
2 years  
 $\Delta$ SphE 0.37 D (32%)  
 $\Delta$ AL 0.15 mm (25%)




**Center distance (+2.50 D add)**  
3 years  
 $\Delta$ SphE 0.46 D (44%)  
 $\Delta$ AL 0.23 mm (35%)



**Orthokeratology**  
2 years  
 $\Delta$ AL 0.27 mm (45%)  
Worn overnight

Soft contact lenses - worn daily

**Pharmacological option**



**Atropine**

0.01%  $\Delta$ SphE 0.39 D  
 $\Delta$ AL 0.13 mm


0.025%  $\Delta$ SphE 0.43 D  
 $\Delta$ AL 0.16 mm

0.05%  $\Delta$ SphE 0.62 D  
 $\Delta$ AL 0.25 mm

**Emerging therapies**

**Combination Atropine (0.01%) and Orthokeratology**

2 years  
 $\Delta$ AL 0.11 mm (27%) compared to Orthokeratology



Red and blue light therapies – safety yet to be established